Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. operates as a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of unmet medical needs and focuses on developing and commercializing therapeutics to treat and prevent human disease. The company's flagship product, TONMYA" (cyclobenzaprine HCl sublingual tablets 2.8 mg), therapy is… Read more
Tonix Pharmaceuticals Holding Corp (TNXP) - Net Assets
Latest net assets as of September 2025: $231.14 Million USD
Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has net assets worth $231.14 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($252.44 Million) and total liabilities ($21.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $231.14 Million |
| % of Total Assets | 91.56% |
| Annual Growth Rate | 65.77% |
| 5-Year Change | 59.23% |
| 10-Year Change | 246.62% |
| Growth Volatility | 278.8 |
Tonix Pharmaceuticals Holding Corp - Net Assets Trend (2008–2024)
This chart illustrates how Tonix Pharmaceuticals Holding Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tonix Pharmaceuticals Holding Corp (2008–2024)
The table below shows the annual net assets of Tonix Pharmaceuticals Holding Corp from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $139.56 Million | +32.25% |
| 2023-12-31 | $105.53 Million | -49.07% |
| 2022-12-31 | $207.18 Million | -5.27% |
| 2021-12-31 | $218.72 Million | +149.54% |
| 2020-12-31 | $87.65 Million | +830.74% |
| 2019-12-31 | $9.42 Million | -60.21% |
| 2018-12-31 | $23.66 Million | -3.87% |
| 2017-12-31 | $24.62 Million | -2.94% |
| 2016-12-31 | $25.36 Million | -37.01% |
| 2015-12-31 | $40.26 Million | +11.55% |
| 2014-12-31 | $36.09 Million | +454.24% |
| 2013-12-31 | $6.51 Million | +579.25% |
| 2012-12-31 | $958.71K | +139.07% |
| 2011-12-31 | $-2.45 Million | -43095.09% |
| 2010-12-31 | $-5.68K | -147.17% |
| 2009-12-31 | $12.04K | -71.93% |
| 2008-12-31 | $42.91K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tonix Pharmaceuticals Holding Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 73067190900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Comprehensive Income | $-255.00K | -0.18% |
| Other Components | $870.50 Million | 623.76% |
| Total Equity | $139.56 Million | 100.00% |
Tonix Pharmaceuticals Holding Corp Competitors by Market Cap
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MedinCell S.A
PINK:MDCLF
|
$176.11 Million |
|
Lagardere SCA
PA:MMB
|
$176.13 Million |
|
Kingstone Companies Inc
NASDAQ:KINS
|
$176.13 Million |
|
Bookook Sec
KO:001270
|
$176.21 Million |
|
Bioneer Corporation
KQ:064550
|
$175.97 Million |
|
Ningbo Joy Intelligent Logistics Technology Co.Ltd.
SHE:301198
|
$175.96 Million |
|
CIVEO CORP. DL -01
F:44C1
|
$175.95 Million |
|
Minera Valparaiso S.A.
SN:MINERA
|
$175.94 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tonix Pharmaceuticals Holding Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 105,525,000 to 139,558,000, a change of 34,033,000 (32.3%).
- Net loss of 130,036,000 reduced equity.
- New share issuances of 140,195,000 increased equity.
- Other comprehensive income decreased equity by 23,000.
- Other factors increased equity by 23,897,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-130.04 Million | -93.18% |
| Share Issuances | $140.19 Million | +100.46% |
| Other Comprehensive Income | $-23.00K | -0.02% |
| Other Changes | $23.90 Million | +17.12% |
| Total Change | $- | 32.25% |
Book Value vs Market Value Analysis
This analysis compares Tonix Pharmaceuticals Holding Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $4290900.00 | $14.96 | x |
| 2009-12-31 | $1204300.00 | $14.96 | x |
| 2010-12-31 | $-568100.00 | $14.96 | x |
| 2011-12-31 | $-245391300.00 | $14.96 | x |
| 2012-12-31 | $95870800.00 | $14.96 | x |
| 2013-12-31 | $651200000.00 | $14.96 | x |
| 2014-12-31 | $3609200000.00 | $14.96 | x |
| 2015-12-31 | $2013100000.00 | $14.96 | x |
| 2016-12-31 | $634025000.00 | $14.96 | x |
| 2017-12-31 | $246160000.00 | $14.96 | x |
| 2018-12-31 | $139200000.00 | $14.96 | x |
| 2019-12-31 | $3751792.83 | $14.96 | x |
| 2020-12-31 | $593017.59 | $14.96 | x |
| 2021-12-31 | $388595.34 | $14.96 | x |
| 2022-12-31 | $709357.35 | $14.96 | x |
| 2023-12-31 | $13315.46 | $14.96 | x |
| 2024-12-31 | $189.53 | $14.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tonix Pharmaceuticals Holding Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -93.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1288.25%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.17x
- Recent ROE (-93.18%) is above the historical average (-98.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -49.25% | 0.00% | 0.00x | 1.07x | $-25.42K |
| 2009 | -256.30% | 0.00% | 0.00x | 1.08x | $-32.07K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.16K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.22 Million |
| 2012 | -0.99% | -504.00% | 0.00x | 2.21x | $-105.32K |
| 2013 | -167.14% | 0.00% | 0.00x | 1.34x | $-11.54 Million |
| 2014 | -76.52% | 0.00% | 0.00x | 1.10x | $-31.23 Million |
| 2015 | -119.35% | 0.00% | 0.00x | 1.17x | $-52.08 Million |
| 2016 | -153.16% | 0.00% | 0.00x | 1.08x | $-41.38 Million |
| 2017 | -85.81% | 0.00% | 0.00x | 1.09x | $-23.58 Million |
| 2018 | -110.25% | 0.00% | 0.00x | 1.11x | $-28.46 Million |
| 2019 | -301.39% | 0.00% | 0.00x | 1.55x | $-29.32 Million |
| 2020 | -57.49% | -1729.17% | 0.03x | 1.12x | $-59.15 Million |
| 2021 | -42.16% | 0.00% | 0.00x | 1.10x | $-114.08 Million |
| 2022 | -55.51% | -1274.00% | 0.04x | 1.09x | $-135.72 Million |
| 2023 | -110.55% | -1501.78% | 0.05x | 1.46x | $-127.21 Million |
| 2024 | -93.18% | -1288.25% | 0.06x | 1.17x | $-143.99 Million |
Industry Comparison
This section compares Tonix Pharmaceuticals Holding Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp (TNXP) | $231.14 Million | -49.25% | 0.09x | $176.11 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |